Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

(2013) S. Munir et al.   CANCER RESEARCH

PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies

(2013) B. J. Chen et al.   CLINICAL CANCER RESEARCH

The role of B7 family molecules in hematologic malignancy

(2012) P. Greaves et al.   BLOOD

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

(2011) Z Peric et al.   LEUKEMIA

Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma

(2011) N W C J van de Donk et al.   LEUKEMIA

Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome

(2011) T Krejsgaard et al.   LEUKEMIA

Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells

(2011) P Amé-Thomas et al.   LEUKEMIA

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients

(2008) T Kozako et al.   LEUKEMIA